JP2021521182A5 - - Google Patents

Info

Publication number
JP2021521182A5
JP2021521182A5 JP2020555523A JP2020555523A JP2021521182A5 JP 2021521182 A5 JP2021521182 A5 JP 2021521182A5 JP 2020555523 A JP2020555523 A JP 2020555523A JP 2020555523 A JP2020555523 A JP 2020555523A JP 2021521182 A5 JP2021521182 A5 JP 2021521182A5
Authority
JP
Japan
Prior art keywords
antagonist antibody
agent
scd73
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027219 external-priority patent/WO2019200256A1/en
Publication of JP2021521182A publication Critical patent/JP2021521182A/ja
Publication of JP2021521182A5 publication Critical patent/JP2021521182A5/ja
Pending legal-status Critical Current

Links

JP2020555523A 2018-04-12 2019-04-12 Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療 Pending JP2021521182A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862656892P 2018-04-12 2018-04-12
US62/656,892 2018-04-12
US201862680255P 2018-06-04 2018-06-04
US62/680,255 2018-06-04
PCT/US2019/027219 WO2019200256A1 (en) 2018-04-12 2019-04-12 Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody

Publications (2)

Publication Number Publication Date
JP2021521182A JP2021521182A (ja) 2021-08-26
JP2021521182A5 true JP2021521182A5 (OSRAM) 2022-04-19

Family

ID=66323956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555523A Pending JP2021521182A (ja) 2018-04-12 2019-04-12 Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療

Country Status (12)

Country Link
US (1) US20210147570A1 (OSRAM)
EP (1) EP3773714A1 (OSRAM)
JP (1) JP2021521182A (OSRAM)
KR (1) KR20200142542A (OSRAM)
CN (1) CN112218657A (OSRAM)
AU (1) AU2019252795A1 (OSRAM)
BR (1) BR112020020826A2 (OSRAM)
CA (1) CA3096674A1 (OSRAM)
IL (1) IL277886A (OSRAM)
MX (1) MX2020010604A (OSRAM)
SG (1) SG11202009839PA (OSRAM)
WO (1) WO2019200256A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
US20230174665A1 (en) * 2020-04-09 2023-06-08 Aprilbio Co., Ltd. Monoclonal Antibodies and Antigen Binding Fragments Thereof for Suppressing CD73 Immune Checkpoint and Uses Thereof
KR20230004726A (ko) * 2020-04-22 2023-01-06 아케소 바이오파마, 인크. 항-cd73/항-pd-1 이중특이항체 및 이의 용도
EP4169948A4 (en) * 2020-06-22 2024-07-10 Innovent Biologics (Suzhou) Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
TW202241441A (zh) * 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
CN117337300A (zh) * 2021-05-21 2024-01-02 百奥泰生物制药股份有限公司 抗pd-1抗体的应用
JP2025520098A (ja) * 2022-05-26 2025-07-01 ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド Ｎｓｃｌｃを処置するためのバイオマーカーおよび方法
EP4545562A4 (en) * 2022-06-22 2025-10-01 Gi Innovation Inc FUSION PROTEIN COMPRISING AN ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF
JP2025541725A (ja) * 2022-12-01 2025-12-23 メディミューン リミテッド 抗ｐｄ－ｌ１抗体及び抗ｃｄ７３抗体を含む癌の治療のための併用療法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA010654B1 (ru) 2004-11-23 2008-10-30 Пи Ай Пи Ко., Лтд. Вмонтированная в стену распределительная коробка водоснабжения
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL2559690T3 (pl) 2005-05-10 2016-09-30 Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
TWI382974B (zh) 2005-12-20 2013-01-21 英塞特公司 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
SI2195017T1 (sl) 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
NO2504364T3 (OSRAM) 2009-11-24 2018-01-06
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
RU2604814C2 (ru) 2011-07-24 2016-12-10 Кьюртек Лтд. Варианты гуманизированных иммуномодулирующих моноклональных антител
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
JP7037359B2 (ja) 2014-10-10 2022-03-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ７３遮断
KR102781223B1 (ko) 2014-11-10 2025-03-12 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
TWI711630B (zh) * 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
CA3016187A1 (en) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies

Similar Documents

Publication Publication Date Title
JP2018508462A5 (OSRAM)
JP2015506944A5 (OSRAM)
JP2018535948A5 (OSRAM)
RU2019106804A (ru) Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4
RU2723047C2 (ru) Средство для лечения множественной миеломы (ММ)
JP2020529469A5 (OSRAM)
JP7663559B2 (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
JP2021525718A5 (OSRAM)
JP2018515493A5 (OSRAM)
JP2022512632A5 (OSRAM)
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2022524204A (ja) 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
JP2022517324A5 (OSRAM)
Laws et al. Inflammation causes resistance to anti-CD20–mediated B cell depletion
KR20240151809A (ko) Fcrn 길항제를 사용하여 근염을 치료하는 방법
CN115551886A (zh) 用于ttr淀粉样变性的联合疗法
Wallukat et al. The First Aptamer-Apheresis Column Specifically for Clearing Blood of β1-Receptor Autoantibodies–A Successful Proof of Principle Using Autoantibody-Positive SHR Rats–
Dietze et al. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
CN114728060A (zh) 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
WO2023223263A1 (en) Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
IL318220A (en) Methods for treating patients with locally advanced or metastatic urinary tract cancer with antibody drug conjugates (ADCs) that bind 191P4D12 proteins in combination with pembrolizumab
JP2024526742A5 (OSRAM)
CN115515620A (zh) 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物